{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:03:45Z","timestamp":1791507825745,"version":"4.3.4"},"reference-count":110,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Hematological malignancies contribute significantly to the overall cancer burden. Certain subtypes, such as hairy cell leukemia (HCL), are chronic and characterized by residual disease after first-line therapy, while others, such as blastic plasmacytoid dendritic cell neoplasm (BPDCN), are aggressive and associated with poor prognosis. Although cornerstone interventions such as radiation and chemotherapy are efficiently used to treat some malignant blood neoplasms, these treatments are often limited by resistance, relapse, lack of enduring disease-free survival\/complete remission, and systemic toxicity. Immunotoxins were developed to improve tumor targeting and have evolved into recombinant immunotoxins (RITs). These novel bioengineered chimeras genetically combine potent cytotoxins with targeted binding domains. In this review, we analyze three FDA-approved RITs, namely, moxetumomab pasudotox, tagraxofusp, and denileukin diftitox, that utilize bacterial toxins from <jats:italic>Pseudomonas<\/jats:italic> and <jats:italic>Corynebacterium diphtheriae<\/jats:italic> to treat refractory\/relapsed (R\/R) HCL, BPDCN, and adult R\/R cutaneous T-cell lymphoma (CTCL), respectively. We reviewed their comprehensive safety profiles, describe complications associated with these fusion proteins, and, finally, discuss potential risk management strategies that may enhance their clinical outcomes. Overall, RITs have demonstrated efficacy, and researchers continue to extend these findings to other indications.<\/jats:p>","DOI":"10.3389\/fphar.2025.1569502","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T05:29:24Z","timestamp":1760678964000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Clinically approved immunotoxins targeting hematological cancers: \u201cthe best of both worlds\u201d"],"prefix":"10.3389","volume":"16","author":[{"given":"Yasmine","family":"Rashad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eckhard U.","family":"Alt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Izadpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebin","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/17474086.2019.1643231","article-title":"Moxetumomab pasudotox for the treatment of relapsed and\/or refractory hairy cell leukemia","volume":"12","author":"Abou Dalle","year":"2019","journal-title":"Expert Rev. Hematol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/biomedicines7010006","article-title":"Clinical activity and tolerability of SL-401 (Tagraxofusp): recombinant diphtheria toxin and Interleukin-3 in hematologic malignancies","volume":"7","author":"Alkharabsheh","year":"2019","journal-title":"Biomedicines"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1010428317692226","DOI":"10.1177\/1010428317692226","article-title":"Immunotoxin: a new tool for cancer therapy","volume":"39","author":"Allahyari","year":"2017","journal-title":"Tumour Biol."},{"key":"B4","article-title":"Citius pharmaceuticals completes enrollment in the pivotal phase 3 study of its cancer immunotherapy I\/ONTAK for the treatment of cutaneous T-Cell lymphoma","author":"Allen","year":"2024","journal-title":"Citius Pharma"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1073\/pnas.83.5.1320","article-title":"Structure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolution","volume":"83","author":"Allured","year":"1986","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B6","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11095-008-9767-0","article-title":"Insertion of the designed helical linker led to increased expression of tf-based fusion proteins","volume":"26","author":"Amet","year":"2009","journal-title":"Pharm. Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.3390\/toxins5081486","article-title":"Immunotoxins: the role of the toxin","volume":"5","author":"Antignani","year":"2013","journal-title":"Toxins (Basel)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the world Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B9","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/9780470292549.ch29","volume-title":"Preclinical safety evaluation of immunotoxins. Preclinical safety evaluation of biopharmaceuticals A sciencebased approach to facilitating clinical trials","author":"Brown","year":"2008"},{"key":"B10","unstructured":"Cancer statistics\n          \n          \n          2024"},{"key":"B11","volume-title":"Diphtheria, tetanus, and pertussis vaccine recommendations","year":"2022"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.addr.2012.09.039","article-title":"Fusion protein linkers: property, design and functionality","volume":"65","author":"Chen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B13","unstructured":"Engineered IL-2-diphtheria toxin fusion protein denileukin diftitox for the treatment of rare forms of cancer\n          \n          \n          2024"},{"key":"B14","article-title":"FDA grants full approval to ONTAK\u00ae (denileukin diftitox) for use in patients with cutaneous T-Cell lymphoma (CTCL)","author":"Co","year":"2024","journal-title":"News Release"},{"key":"B15","article-title":"FDA accepts BLA for denileukin diftitox in cutaneous persistent\/recurrent T-Cell lymphoma","author":"Conroy","year":"2022","journal-title":"CancerNetwork"},{"key":"B16","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1080\/17512433.2019.1662297","article-title":"Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm","volume":"12","author":"Economides","year":"2019","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B17","unstructured":"Eisai submits marketing authorization application in Japan for anticancer agent denileukin diftitox (genetic recombinant) for cutaneous t-cell lymphoma and peripheral t-cell lymphoma\n          \n          \n          2024"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3087","DOI":"10.3390\/cancers12113087","article-title":"CD123 as a biomarker in hematolymphoid malignancies: principles of detection and targeted therapies","volume":"12","author":"El","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1365-2141.2009.07668.x","article-title":"Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis","volume":"145","author":"Else","year":"2009","journal-title":"Br. J. Haematol."},{"key":"B20","article-title":"The largest prospective BPDCN study (N=84) of treatment-naive and previously treated patients","year":"2020","journal-title":"Elzonris"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3942","DOI":"10.1182\/blood.V122.21.3942.3942","article-title":"Preclinical studies of SL-401, a targeted therapy directed to the interleukin-3 receptor (IL3-R), in blastic plasmacytoid dendritic cell neoplasm (BPDCN): potent activity in BPDCN cell lines, primary tumor, and in an in vivo model","volume":"122","author":"Fanny","year":"2013","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med."},{"key":"B23","unstructured":"Letter response to BLA\n          \n          \n          2008"},{"key":"B24","unstructured":"FDA highlights of lumoxiti prescribing information"},{"key":"B25","unstructured":"Tagraxofusp-erzs FDA approval summary review"},{"key":"B26","unstructured":"FDA approves moxetumomab pasudotox-tdfk for hairy cell leukemia\n          \n          \n          2020"},{"key":"B27","article-title":"AstraZeneca\u2019s letter to the FDA about discontinuing lumoxiti","year":"2023","journal-title":"Lett. Novemb. 18th"},{"key":"B28","unstructured":"FDA\n          \n          \n          2024"},{"key":"B29","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1078\/1438-4221-00302","article-title":"Recombinant immunotoxins for treating cancer","volume":"293","author":"FitzGerald","year":"2004","journal-title":"Int. J. Med. Microbiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1182\/blood-2022-166916","article-title":"Efficacy and safety of E7777 (improved purity denileukin diftitox [ONTAK]) in patients with relapsed or refractory cutaneous T-cell lymphoma: results from pivotal study 302","volume":"140","author":"Foss","year":"2022","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2174\/1568009023333944","article-title":"Diphtheria fusion protein therapy of chemoresistant malignancies","volume":"2","author":"Frankel","year":"2002","journal-title":"Curr. Cancer Drug Targets"},{"key":"B32","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/protein\/15.11.871","article-title":"An analysis of protein domain linkers: their classification and role in protein folding","volume":"15","author":"George","year":"2002","journal-title":"Protein Eng."},{"key":"B33","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.beha.2015.10.015","article-title":"Hairy cell leukemia: past, present and future","volume":"28","author":"Getta","year":"2015","journal-title":"Best. Pract. Res. Clin. Haematol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1111\/bjh.14207","article-title":"Treatment outcomes and secondary cancer incidence in young patients with hairy cell leukaemia","volume":"175","author":"Getta","year":"2016","journal-title":"Br. J. Haematol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.3389\/fimmu.2020.01106","article-title":"Defining the threshold IL-2 signal required for induction of selective Treg cell responses using engineered IL-2 muteins","volume":"11","author":"Ghelani","year":"2020","journal-title":"Front. Immunol."},{"key":"B36","volume-title":"Wintrobe's clinical hematology","author":"Greer","year":"2018"},{"key":"B37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1053\/j.seminhematol.2013.11.005","article-title":"Management of relapses after hematopoietic cell transplantation in T-cell Non-Hodgkin lymphomas","volume":"51","author":"Hamadani","year":"2014","journal-title":"Semin. Hematol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/CJI.0b013e3181cd1164","article-title":"A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice","volume":"33","author":"Hansen","year":"2010","journal-title":"J. Immunother."},{"key":"B39","doi-asserted-by":"publisher","first-page":"4936","DOI":"10.1002\/cncr.33145","article-title":"Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin","volume":"126","author":"Hassan","year":"2020","journal-title":"Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/jnci\/djp110","article-title":"Whatever happened to immunotoxins? Research, and hope, are still alive","volume":"101","author":"Holzman","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"B41","unstructured":"A trial of E7777 in persistent and recurrent cutaneous T-Cell lymphoma\n          \n          \n          2022"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/sj.gt.3302557","article-title":"Protein toxins: intracellular trafficking for targeted therapy","volume":"12","author":"Johannes","year":"2005","journal-title":"Gene Ther."},{"key":"B43","article-title":"Corynebacterium Diphtheriae","volume-title":"Medical microbiology","author":"John","year":"1996"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1111\/cas.14906","article-title":"Phase II study of E7777 in Japanese patients with relapsed\/refractory peripheral and cutaneous T-cell lymphoma","volume":"112","author":"Kawai","year":"2021","journal-title":"Cancer Sci."},{"key":"B45","doi-asserted-by":"publisher","first-page":"645","DOI":"10.3389\/fonc.2019.00645","article-title":"Antibody-Directed therapies: toward a durable and tolerable treatment platform for CTCL","volume":"9","author":"Khan","year":"2019","journal-title":"Front. Oncol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.bbmt.2013.01.027","article-title":"Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation","volume":"19","author":"Kharfan-Dabaja","year":"2013","journal-title":"Biol. Blood Marrow Transpl."},{"key":"B47","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.xphs.2019.10.037","article-title":"Critical issues in the development of immunotoxins for anticancer therapy","volume":"109","author":"Kim","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"B48","doi-asserted-by":"publisher","first-page":"043","DOI":"10.15407\/biotech6.04.043","article-title":"Immunobiology of diphtheria. Recent approaches for the prevention, diagnosis, and treatment of disease","volume":"6","author":"Kolybo","year":"2013","journal-title":"Biotechnol. Acta"},{"key":"B49","doi-asserted-by":"publisher","first-page":"6398","DOI":"10.1158\/1078-0432.CCR-11-0487","article-title":"Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox","volume":"17","author":"Kreitman","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.3390\/biom10081140","article-title":"Development of recombinant immunotoxins for hairy cell leukemia","volume":"10","author":"Kreitman","year":"2020","journal-title":"Biomolecules"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1200\/JCO.2011.38.1756","article-title":"Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia","volume":"30","author":"Kreitman","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia","volume":"32","author":"Kreitman","year":"","journal-title":"Leukemia"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1182\/blood-2017-09-803072","article-title":"Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up","volume":"131","author":"Kreitman","year":"","journal-title":"Blood, J. Am. Soc. Hematol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-020-01004-y","article-title":"Moxetumomab pasudotox in heavily pre-treated patients with relapsed\/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial","volume":"14","author":"Kreitman","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1084\/jem.155.6.1797","article-title":"In vivo therapy of a murine B cell tumor (BCL1) using antibody-ricin A chain immunotoxins","volume":"155","author":"Krolick","year":"1982","journal-title":"J. Exp. Med."},{"key":"B56","unstructured":"Citius buys out license to Ontak replacement from dr. Reddy's for $40M\n          \n          \n            \n              LaHucik\n              K.\n            \n          \n          \n          2024"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1268979","DOI":"10.3389\/fimmu.2023.1268979","article-title":"Targeting regulatory T cells by E7777 enhances CD8 T-cell\u2013mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models","volume":"14","author":"Mahdi","year":"2023","journal-title":"Front. Immunol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1002\/ajh.25653","article-title":"Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Maitre","year":"2019","journal-title":"Am. J. Hematol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood.v90.5.2020","article-title":"Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors","volume":"90","author":"Mansfield","year":"1997","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3892\/ijmm.6.5.509","article-title":"Recombinant immunotoxins for the treatment of Hodgkin's disease","volume":"6","author":"Matthey","year":"2000","journal-title":"Int. J. Mol. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3389\/fimmu.2020.01261","article-title":"Immunogenicity of immunotoxins containing pseudomonas Exotoxin A: causes, consequences, and mitigation","volume":"11","author":"Mazor","year":"2020","journal-title":"Front. Immunol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"8571","DOI":"10.1073\/pnas.1405153111","article-title":"Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes","volume":"111","author":"Mazor","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/j.ajpath.2018.04.016","article-title":"Strategies to reduce the immunogenicity of recombinant immunotoxins","volume":"188","author":"Mazor","year":"","journal-title":"Am. J. Pathol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"E733","DOI":"10.1073\/pnas.1717063115","article-title":"Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity","volume":"115","author":"Mazor","year":"","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B65","first-page":"154","article-title":"The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas","volume":"26","author":"McCarthy","year":"2006","journal-title":"Iowa Orthop. J."},{"key":"B66","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1055\/s-0039-1700507","article-title":"Immunotoxins: targeted toxin delivery for cancer therapy","volume":"1","author":"Mei","year":"2019","journal-title":"Pharm. Fronts"},{"key":"B67","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1083\/jcb.140.4.733","article-title":"Toxin entry: retrograde transport through the secretory pathway","volume":"140","author":"Michael Lord","year":"1998","journal-title":"J. cell Biol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3389\/fmicb.2015.00963","article-title":"Pseudomonas Exotoxin A: optimized by evolution for effective killing","volume":"6","author":"Michalska","year":"2015","journal-title":"Front. Microbiol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/jnci\/55.2.473","article-title":"Antitumor effects of antibody-diphtheria toxin conjugates. II. Immunotherapy with conjugates directed against tumor antigens induced by simian virus 40","volume":"55","author":"Moolten","year":"1975","journal-title":"J. Natl. Cancer Inst."},{"key":"B70","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3390\/toxins3030294","article-title":"Mechanism of diphtheria toxin catalytic domain delivery to the eukaryotic cell cytosol and the cellular factors that directly participate in the process","volume":"3","author":"Murphy","year":"2011","journal-title":"Toxins"},{"key":"B72","unstructured":"Accessed February 2024"},{"key":"B73","unstructured":"A trial of E7777 in persistent and recurrent cutaneous T-Cell lymphoma"},{"key":"B74","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1080\/08820130500496878","article-title":"A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry","volume":"35","author":"Olejniczak","year":"2006","journal-title":"Immunol. Invest"},{"key":"B75","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1146\/annurev.bi.61.070192.001555","article-title":"Recombinant toxins as novel therapeutic agents","volume":"61","author":"Pastan","year":"1992","journal-title":"Annu. Rev. Biochem."},{"key":"B76","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrc1891","article-title":"Immunotoxin therapy of cancer","volume":"6","author":"Pastan","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in blastic plasmacytoid dendritic-cell neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B78","doi-asserted-by":"publisher","first-page":"3032","DOI":"10.1200\/JCO.22.00034","article-title":"Long-Term benefits of tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm","volume":"40","author":"Pemmaraju","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/BF02128183","article-title":"Immunotoxins against solid tumors","volume":"114","author":"Pirker","year":"1988","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B80","volume-title":"Citius pharmaceuticals, Inc. Receives regulatory guidance from the U.S. food and Drug Administration (FDA) regarding the planned resubmission of the BLA for LYMPHIR\u2122","year":"2023"},{"key":"B81","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.leukres.2011.07.033","article-title":"Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation, lacking cutaneous involvement: case series and literature review","volume":"36","author":"Rauh","year":"2012","journal-title":"Leuk. Res."},{"key":"B83","article-title":"Citius pharmaceuticals announces FDA acceptance of the BLA resubmission of LYMPHIR\u2122 (denileukin diftitox) for the treatment of adults with relapsed or refractory cutaneous T-Cell lymphoma","author":"Salsburg","year":"2024","journal-title":"Citius Pharma News"},{"key":"B84","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1158\/1078-0432.CCR-01-0450","article-title":"Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display","volume":"8","author":"Salvatore","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"B85","unstructured":"Denileukin diftitox BLA resubmitted for CTCL after addressing FDA concerns\n          \n          \n            \n              Sava\n              J.\n            \n          \n          \n          2024"},{"key":"B86","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.3390\/toxins7104067","article-title":"Mutagenic deimmunization of diphtheria toxin for use in biologic drug development","volume":"7","author":"Schmohl","year":"2015","journal-title":"Toxins (Basel)"},{"key":"B87","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1182\/blood.v83.10.2906.2906","article-title":"2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia","volume":"83","author":"Seymour","year":"1994","journal-title":"Blood"},{"key":"B88","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/sj.leu.2400513","article-title":"Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up","volume":"11","author":"Seymour","year":"1997","journal-title":"Leukemia"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.3389\/fmicb.2019.02340","article-title":"Targeted diphtheria toxin-based therapy: a review article","volume":"10","author":"Shafiee","year":"2019","journal-title":"Front. Microbiol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"564","DOI":"10.5858\/arpa.2013-0101-RS","article-title":"Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic review","volume":"138","author":"Shi","year":"2014","journal-title":"Arch. Pathol. Lab. Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1254\/fpj.22032","article-title":"Preclinical and clinical researches of Denileukin Diftitox (genetical Recombination)(Remitoro\u00ae), a novel agent for T-cell lymphoma","volume":"157","author":"Shiiba","year":"2022","journal-title":"Nihon Yakurigaku zasshi Folia Pharmacol. Jpn."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/ajh.27737","article-title":"Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): 2025 update on diagnosis, pathophysiology, risk assessment, and management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am. J. Hematol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"9514","DOI":"10.1073\/pnas.91.20.9514","article-title":"Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity","volume":"91","author":"Siegall","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B94","doi-asserted-by":"publisher","first-page":"1386190","DOI":"10.3389\/fonc.2024.1386190","article-title":"Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers","volume":"14","author":"Skorupan","year":"2024","journal-title":"Front. Oncol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"2","DOI":"10.7603\/s40730-015-0002-4","article-title":"Immune-O-Toxins as the magic bullet for therapeutic purposes","volume":"2","author":"Srivastava","year":"2015","journal-title":"Biomed. Res. Ther."},{"key":"B96","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3109\/10428194.2011.565097","article-title":"Purine analog toxicity in patients with hairy cell leukemia","volume":"52","author":"Tadmor","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"B97","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41409-018-0265-7","article-title":"Patient eligibility for hematopoietic stem cell transplantation: a review of patient-associated variables","volume":"54","author":"Tay","year":"2019","journal-title":"Bone Marrow Transpl."},{"key":"B98","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000443526","article-title":"Paul Ehrlich (1854-1915) and his contributions to the foundation and birth of translational medicine","volume":"8","author":"Valent","year":"2016","journal-title":"J. Innate Immun."},{"key":"B99","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jim.2017.05.008","article-title":"Ontak-like human IL-2 fusion toxin","volume":"448","author":"Wang","year":"2017","journal-title":"J. Immunol. Methods"},{"key":"B100","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-13278-5","volume-title":"Molecular therapies of cancer","author":"Weber","year":"2015"},{"key":"B101","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1111\/j.1742-4658.2011.08182.x","article-title":"A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer","volume":"278","author":"Weldon","year":"2011","journal-title":"FEBS J."},{"key":"B102","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1021\/acs.bioconjchem.5b00190","article-title":"Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A","volume":"26","author":"Weldon","year":"2015","journal-title":"Bioconjug Chem."},{"key":"B103","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ijmm.2008.08.003","article-title":"Pseudomonas exotoxin A: from virulence factor to anti-cancer agent","volume":"299","author":"Wolf","year":"2009","journal-title":"Int. J. Med. Microbiol."},{"key":"B104","article-title":"BLA submitted to the FDA for denileukin diftitox in cutaneous Persistent\/Recurrent T-Cell lymphoma","author":"Wrigley","year":"2022","journal-title":"CancerNetwork"},{"key":"B105","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/0092-8674(78)90099-5","article-title":"One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell","volume":"15","author":"Yamaizumi","year":"1978","journal-title":"Cell"},{"key":"B106","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s11899-017-0378-x","article-title":"Predicting chemotherapy resistance in AML","volume":"12","author":"Yeung","year":"2017","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"B107","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3343\/alm.2014.34.2.148","article-title":"A rare case of acute leukemic presentation of blastic plasmacytoid dendritic cell neoplasm without cutaneous lesions","volume":"34","author":"Yu","year":"2014","journal-title":"Ann. Lab. Med."},{"key":"B108","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3390\/toxins9080236","article-title":"Bacterial toxins for cancer therapy","volume":"9","author":"Zahaf","year":"2017","journal-title":"Toxins (Basel)"},{"key":"B109","doi-asserted-by":"publisher","first-page":"21791","DOI":"10.1016\/s0021-9258(20)80612-7","article-title":"Mechanism of action of Pseudomonas exotoxin. Identification of a rate-limiting step","volume":"268","author":"Zdanovsky","year":"1993","journal-title":"J. Biol. Chem."},{"key":"B110","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1158\/1535-7163.MCT-19-0890","article-title":"Site-Specific PEGylation of Anti-Mesothelin recombinant immunotoxins increases half-life and antitumor activity","volume":"19","author":"Zheng","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"B111","doi-asserted-by":"publisher","first-page":"7929286","DOI":"10.1155\/2017\/7929286","article-title":"Recombinant immunotoxin therapy of glioblastoma: smart design, key findings, and specific challenges","volume":"2017","author":"Zhu","year":"2017","journal-title":"Biomed. Res. Int."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1569502\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T05:29:29Z","timestamp":1760678969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1569502\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":110,"alternative-id":["10.3389\/fphar.2025.1569502"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1569502","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"article-number":"1569502"}}